1. Scrip

Myovant Expects Gradual Growth For Myfembree With Endometriosis Approval

 
• By Joseph Haas

Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.

Women's health
Myovant hopes second indication for Myfembree will spur women's health franchise • Source: Shutterstock

Myovant Sciences Ltd. and Pfizer Inc.’s Myfembree has not yet been a roaring success in the sluggish women’s health space, but when detailing the product’s new approval for the management of moderate-to-severe endometriosis pain in premenopausal women on 8 August, the company presented a picture of momentum and efficiency that will be enhanced by a second indication.

Myovant is seeking to build a successful women’s health business with Myfembree (relugolix/estradiol/norethindrone), which obtained US Food and Drug Administration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.